The Latest Breaking News from Beam

August 24 marks the Independence Day of Ukraine as well as six months since Russia invaded the country.

The Food and Drug Administration placed a cancer study from Beam Therapeutics on hold Monday, leading Beam stock to topple.

Verve Therapeutics said Tuesday it edited the genes of someone with high cholesterol. The first-ever move could push VERV stock higher.

Our round-up of stories this week includes Ocado Retail, Hay &Kilner, the North East BIC and durhamlane

BMO Capital initiated coverage on Beam Therapeutics Inc (NASDAQ:BEAM) with a Market Perform rating and a price target of 41. BMO writes that it appreciates the high potential of Beam's next-generation editing approach, but clinical validation is yet to be established. Preclinical base editing data point to a favorable benefit/risk profile. Also Read: Pfizer, Beam…

A start date has not been set, but organisers plan to have them ready to use by the end of this month.

The e-bike trial is being driven by Lake Macquarie City's economic arm Dantia

There have been plenty of new builds across Wearside in recent years for locals and visitors alike to make the most of, with many more coming in the pipeline.

Renowned investor Cathie Wood of ARK Invest is known for her eye for stocks with enormous upside potential. Despite recent macro headwinds, the biotech industry is expected to grow tremendously in 2022, supported by strong demand for healthcare and medical products and increasing investments in R&D. Given these factors, Wall…